PLX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own PLX shares is 54, representing 5.2% of the company's common stock.

DENALI ADVISORS LLC, in the last quarter, reduced its stake in PLX by -100% restricting it's holding to 0 shares of worth nearly -. ADVISORY SERVICES NETWORK, LLC also lessened -100% of the PLX shares from its portfolio, reducing its holding to 0 shares of worth -. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. also shunned PLX shares holding by -100% last quarter which brought its holding to 0 shares worth -.

As per its latest 13F filing, PROSHARE ADVISORS LLC increased its stake in PLX by 10.64% in the last quarter. The institutional holder raised its holding to 12.15 thousand shares having worth more than $15.31K. VIRTU FINANCIAL LLC also added 100% more shares of PLX to its portfolio, raising its holding to 157.52 thousand shares of worth $198.00K. TWO SIGMA SECURITIES, LLC also increased its PLX shares holding by 91.83% which brought its holding to 85.31 thousand shares worth $107.49K.

The insider with the most stakes in PLX is Camber Capital Management LLC , 10 percent owner at the company. Additionally, PLX stock is highly held by Bronfeld Zeev and 10 percent owner Bio-Cell Ltd among others.

Company executives, directors, and other insiders own 14.53% percent of Protalix BioTherapeutics, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which PLX insiders have sold stock, totaling 0 shares. Insiders that have sold shares include DEXCEL PHARMA TECHNOLOGIES LTD., CAMBER CAPITAL MANAGEMENT LLC, and BIO-CELL LTD.

There have been 0 transaction(s) during the past 6-months in which Protalix BioTherapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 0 Protalix BioTherapeutics, Inc. shares are held by insiders, which represents about 14.53% of PLX stock.

PLX 10 percent owner, Camber Capital Management LLC holds the largest portfolio of the company's shares. PLX shares owned by Camber total nearly 10.78 million.

PROSHARE ADVISORS LLC is the largest institutional owner in PLX which holds 12.15 thousand shares worth $15.31K or 0.02% of the total PLX shares outstanding followed by DENALI ADVISORS LLC with ownership of 0 shares representing 0% of the PLX ownership. ADVISORY SERVICES NETWORK, LLC is the third largest stakeholder with 0 shares or 0% of the ownership worth more than -.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the PLX is concerned, it is a stock which is optionable.

Number of PLX shares short is 4.30M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 73.63M shares of PLX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, PLX has 54.75M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for PLX is 6.51.